

From: [OC GCP Questions](#)
To: [redacted]
Subject: 28 day mortality
Date: Wednesday, May 21, 2014 9:08:05 AM

Good morning --

My office only answers general good clinical practice questions. You might want to reach out to the Center for Drugs (CDER) at druginfo@fda.hhs.gov or the Center for Biologics (CBER) at ocod@fda.hhs.gov

Kind regards,

Doreen M. Kezer, MSN
Senior Health Policy Analyst
Office of Good Clinical Practice
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

-----Original Message-----

From: [redacted]
Sent: Wednesday, May 21, 2014 8:14 AM
To: OC GCP Questions
Subject: 28 day mortality

Good morning, I write from Guatemala. I ask for your help. Where I can find the definition and use of the 28 day mortality? I work in PICU of the [redacted], my colleagues and I find this a point break used in your trials and I need to use as iindicator.

Thank you
[redacted]